T. Rowe Price Investment Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

T. Rowe Price Investment Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$83.3M	Buy	+4,280,624	New	+$77.6M	0.05%	305
2026 Q1	–	Sell	-3,557	Closed	-$47K	–	827
2025 Q4	$47K	Buy	+3,557	New	+$42K	﹤0.01%	668
2025 Q3	–	Sell	-509	Closed	-$25K	–	911
2025 Q2	$25K	Buy	+509	New	+$20.7K	﹤0.01%	669
2024 Q2	–	Sell	-1,095,101	Closed	-$55M	–	646
2024 Q1	$55M	Sell	1,095,101 -125,501	-10%	-$6.81M	0.03%	377
2023 Q4	$73.7M	Buy	1,220,602 +5,879	+0.5%	+$303K	0.05%	325
2023 Q3	$69.2M	Buy	1,214,723 +65,914	+6%	+$3.64M	0.05%	312
2023 Q2	$58.6M	Buy	+1,148,809	New	+$30.9M	0.04%	354

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

T. Rowe Price Investment Management's MLTX Position: Q2 2026 in Review

T. Rowe Price Investment Management opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 4,280,624 shares worth $83.3M. The stake represents 0.05% of the portfolio and ranks #305 among its holdings. This is a return to the name: T. Rowe Price Investment Management previously reported a position in MLTX as recently as Q4 2025.

T. Rowe Price Investment Management first reported a position in MLTX in Q2 2023 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

T. Rowe Price Investment Management held 4,280,624 shares of MoonLake Immunotherapeutics worth $83.3M as of Q2 2026.
MoonLake Immunotherapeutics was a new T. Rowe Price Investment Management position in Q2 2026.
MoonLake Immunotherapeutics made up 0.05% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #305 holding.
T. Rowe Price Investment Management first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 7 quarters since.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.